KLKatia Lemdani

Katia Lemdani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katia Lemdani has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Anne-Sophie Beignon

    Université Paris-Saclay, Inserm, CEA, U1184, Immunological Diseases, Microbiology and Innovative Therapies (IDMIT)

    1 shared publication
  • Caroline Manet

    Mouse Genetics Laboratory, Department of Genomes and Genetics, Institut Pasteur, Paris, France

    1 shared publication
  • Catherine Chapon

    Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Fontenay-aux-Roses & Le Kremlin-Bicêtre, Inserm, Paris, CEA, France

    1 shared publication
  • Ernesto Marcos Lopez

    Immunology of Viral Infections and Autoimmune Diseases (IMVA), IDMIT Department, Institut de Biologie François-Jacob (IBJF), University Paris-Sud—INSERM U1184, CEA, 92265 Fontenay-Aux-Roses, France

    1 shared publication
  • Lina Cheraitia

    Immunology of Viral Infections and Autoimmune Diseases (IMVA), IDMIT Department, Institut de Biologie François-Jacob (IBJF), University Paris-Sud—INSERM U1184, CEA, 92265 Fontenay-Aux-Roses, France

    1 shared publication
  • Matthieu Van Tilbeurgh

    Immunology of Viral Infections and Autoimmune Diseases (IMVA), IDMIT Department, Institut de Biologie François-Jacob (IBJF), University Paris-Sud—INSERM U1184, CEA, 92265 Fontenay-Aux-Roses, France

    1 shared publication

Latest Publications

  • Open Access

    Predictive Markers of Immunogenicity and Efficacy for Human Vaccines

    by Matthieu Van Tilbeurgh, Katia Lemdani, Anne-Sophie Beignon, Catherine Chapon, Nicolas Tchitchek, Lina Cheraitia, Ernesto Marcos Lopez, Quentin Pascal, Roger Le Grand, Pauline Maisonnasse, et al.

    Vaccines represent one of the major advances of modern medicine. Despite the many successes of vaccination, continuous efforts to design new vaccines are needed to fight “old” pandemics, such as tuberculosis and malaria, as well as emerging pathogens, such as Zika virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Vaccination aims at reaching sterilizing immunity, however assessing vaccine efficacy is still challenging and underscores the need for a better understanding of immune protective responses. Identifying reliable predictive markers of immunogenicity can help to select and develop promising vaccine candidates during early preclinical studies and can lead to improved, personalized, vaccination strategies. A systems biology approach is increasingly being adopted to address these major challenges using multiple high-dimensional technologies combined with in silico models. Although the goal is to develop predictive models of vaccine efficacy in humans, applying this approach to animal models empowers basic and translational vaccine research. In this review, we provide an overview of vaccine immune signatures in preclinical models, as well as in target human populations. We also discuss high-throughput technologies used to probe vaccine-induced responses, along with data analysis and computational methodologies applied to the predictive modeling of vaccine efficacy.